Serial #79316849
LIVE

Serial Number

79316849

Owner

Lunac Therapeutics Limited

Attorney

Matthew L. Frisbee

Filing Date

Apr 16, 2021

Add to watchlist:

No watchlists yet
View on USPTO

Serial #79316849 Trademark

Serial Number: 79316849 • Registration: 6823172

Serial #79316849 is a trademark filed by Lunac Therapeutics Limited on April 16, 2021. The trademark is classified under Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Lunac Therapeutics Limited (2 trademarks)

Secretariat,

Entity Type: 99

Trademark Details

Filing Date

April 16, 2021

Registration Date

August 23, 2022

Published for Opposition

June 7, 2022

Goods & Services

Treatment of materials, namely manipulation of oral small molecules, for use as anticoagulants; custom manufacture of chemicals, medicines, pharmaceuticals and anticoagulants; custom manufacture of therapeutic products and medical diagnostic products; consultancy, advisory and information in connection with all of the aforementioned services

Medical and veterinary preparations, namely pharmaceutical preparations for the treatment of blood disorders, conditions of the immune system, cardiological disorders, hormonal conditions, cancer, obstetrical conditions and complications, gynecological conditions, infectious diseases, neonatal illnesses, kidney diseases, neurological conditions, orthopedic conditions, respiratory illnesses, conditions of the urinary tract systems and male reproductive organs, antibiotics for patients undergoing surgical procedures, bacteriological preparations for patients in intensive care, autoimmune diseases and hereditary diseases; medical diagnostic preparations, chemicals, agents for detecting thrombotic conditions, reagents for detecting thrombotic conditions; anticoagulants; anticoagulants for the treatment of medical conditions; anticoagulants for the treatment of thrombosis and blood clots; anticoagulants for use in the discovery, preclinical and clinical development of therapeutic products and medical diagnostic products; medicines and pharmaceuticals, namely anticoagulants for use in the discovery, preclinical and clinical development of therapeutic products and medical diagnostic products

Scientific and technological services, namely providing scientific research for medical purposes in the field of blood disorders, conditions of the immune system, cardiological disorders, hormonal conditions, cancer, obstetrical conditions and complications, gynecological conditions, infectious diseases, neonatal illnesses, kidney diseases, neurological conditions, orthopedic conditions, respiratory illnesses, conditions of the urinary tract systems and male reproductive organs, patients undergoing surgical procedures, patients in intensive care, autoimmune diseases and hereditary diseases; research and design in relation to science, technology, pharmaceuticals, medicine, blood, thrombosis and/or anticoagulants; preparation of scientific reports on anticoagulants for medical and veterinary purposes; engineering of medicines and/or pharmaceuticals; engineering of anticoagulants; engineering of medicines and/or pharmaceuticals for the treatment of thrombosis and blood clotting; scientific services relating to the discovery, preclinical and clinical development of therapeutic and medical diagnostic products; consultancy, advisory and information in connection with all of the aforementioned services

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
May 14, 2026 NREP
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jun 12, 2025 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jun 12, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jun 12, 2025 REAP
FINAL DECISION TRANSACTION PROCESSED BY IB
Dec 28, 2022 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Dec 2, 2022 FICS
FINAL DISPOSITION PROCESSED
Dec 2, 2022 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Nov 23, 2022 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Aug 23, 2022 NRCC
REGISTERED-PRINCIPAL REGISTER
Aug 23, 2022 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 7, 2022 NPUB
PUBLISHED FOR OPPOSITION
Jun 7, 2022 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 18, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
May 2, 2022 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 26, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 25, 2022 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Apr 25, 2022 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Apr 5, 2022 GNFN
FINAL REFUSAL E-MAILED
Apr 5, 2022 GNFR
FINAL REFUSAL WRITTEN
Apr 5, 2022 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 23, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 22, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 22, 2022 TROA
REFUSAL PROCESSED BY IB
Jan 1, 2022 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Dec 14, 2021 RFCS
REFUSAL PROCESSED BY MPU
Dec 14, 2021 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Dec 11, 2021 RFCR
NON-FINAL ACTION WRITTEN
Dec 10, 2021 CNRT
ASSIGNED TO EXAMINER
Dec 9, 2021 DOCK
APPLICATION FILING RECEIPT MAILED
Aug 10, 2021 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 5, 2021 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jul 29, 2021 REPR